Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
about
Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.Overcoming platinum resistance in ovarian carcinoma.Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.Durable response after just one cycle of belotecan-based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma.The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.
P2860
Q33395064-50FA3C8E-0924-4373-9251-423C97A8CFCCQ34233273-633D2029-5C7A-436F-B660-57774E6BFE3FQ38494130-AF09DAC5-2DA3-4D53-B3C0-95C66A225105Q42709012-3CBD27CD-C7D9-404D-8CF1-266D37AB63AAQ43010573-70D47DED-0B75-40D7-B31A-995ADC98F836Q47220295-7B33659C-F3DC-4D98-B992-1572E4832388Q55493644-C8F1B0C9-3F19-4DFE-BA70-027466A20795
P2860
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Phase II evaluation of CKD-602 ...... or -resistant ovarian cancer.
@ast
Phase II evaluation of CKD-602 ...... or -resistant ovarian cancer.
@en
type
label
Phase II evaluation of CKD-602 ...... or -resistant ovarian cancer.
@ast
Phase II evaluation of CKD-602 ...... or -resistant ovarian cancer.
@en
prefLabel
Phase II evaluation of CKD-602 ...... or -resistant ovarian cancer.
@ast
Phase II evaluation of CKD-602 ...... or -resistant ovarian cancer.
@en
P2093
P1433
P1476
Phase II evaluation of CKD-602 ...... or -resistant ovarian cancer.
@en
P2093
Hyo-Pyo Lee
Jong-Hyeok Kim
Joo-Hyun Nam
Kyung-Hee Lee
Sang-Soo Seo
Sang-Yoon Park
Sang-Young Ryu
Soon-Beom Kang
Yong Sang Song
Yung-Jue Bang
P304
P356
10.1016/J.YGYNO.2007.11.023
P407
P577
2008-04-10T00:00:00Z